396 related articles for article (PubMed ID: 25193987)
1. PD-L1 expression in nonclear-cell renal cell carcinoma.
Choueiri TK; Fay AP; Gray KP; Callea M; Ho TH; Albiges L; Bellmunt J; Song J; Carvo I; Lampron M; Stanton ML; Hodi FS; McDermott DF; Atkins MB; Freeman GJ; Hirsch MS; Signoretti S
Ann Oncol; 2014 Nov; 25(11):2178-2184. PubMed ID: 25193987
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 expression and infiltration by CD4
Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness.
Chang K; Qu Y; Dai B; Zhao JY; Gan H; Shi G; Zhu Y; Shen Y; Zhu Y; Zhang H; Ye D
Sci Rep; 2017 May; 7(1):2074. PubMed ID: 28522811
[TBL] [Abstract][Full Text] [Related]
4. Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?
Abbas M; Steffens S; Bellut M; Becker JU; Großhennig A; Eggers H; Wegener G; Kuczyk MA; Kreipe HH; Grünwald V; Schrader AJ; Ivanyi P
Med Oncol; 2016 Jun; 33(6):59. PubMed ID: 27165272
[TBL] [Abstract][Full Text] [Related]
5. Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study.
Fay AP; Signoretti S; Callea M; Telό GH; McKay RR; Song J; Carvo I; Lampron ME; Kaymakcalan MD; Poli-de-Figueiredo CE; Bellmunt J; Hodi FS; Freeman GJ; Elfiky A; Choueiri TK
J Immunother Cancer; 2015; 3():3. PubMed ID: 25767716
[TBL] [Abstract][Full Text] [Related]
6. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of pd-1, pd-l1, and cytotoxic T-lymphocyteassociated protein 4 expressions together with clinicopathological findings in clear cell, papillary, and chromophobe types of renal cell carcinoma.
Inceman M; Toyran T; Bayazit Y; Izol V; Erdogan S
Pol J Pathol; 2022; 73(3):181-190. PubMed ID: 36734432
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 Expression is Associated With Poor Prognosis in Renal Cell Carcinoma.
Carlsson J; Sundqvist P; Kosuta V; Fält A; Giunchi F; Fiorentino M; Davidsson S
Appl Immunohistochem Mol Morphol; 2020 Mar; 28(3):213-220. PubMed ID: 31058656
[TBL] [Abstract][Full Text] [Related]
10. Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer.
Möller K; Fraune C; Blessin NC; Lennartz M; Kluth M; Hube-Magg C; Lindhorst L; Dahlem R; Fisch M; Eichenauer T; Riechardt S; Simon R; Sauter G; Büscheck F; Höppner W; Matthies C; Doh O; Krech T; Marx AH; Zecha H; Rink M; Steurer S; Clauditz TS
Int Urol Nephrol; 2021 Dec; 53(12):2493-2503. PubMed ID: 33797012
[TBL] [Abstract][Full Text] [Related]
11. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
[TBL] [Abstract][Full Text] [Related]
12. Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features.
Hong B; Cai L; Wang J; Liu S; Zhou J; Ma K; Zhang J; Zhou B; Peng X; Zhang N; Gong K
Clin Genitourin Cancer; 2019 Apr; 17(2):97-104.e1. PubMed ID: 30522901
[TBL] [Abstract][Full Text] [Related]
13. Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Non-Clear Cell Renal Cell Carcinoma.
Chrabańska M; Szweda-Gandor N; Rynkiewicz M; Hraboš D; Drozdzowska B
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612724
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological implications of the expression of vascular endothelial growth factor and programmed death ligand 1 in clear-cell renal cell carcinoma.
Lee KS; Yun S; Lee K; Moon S; Choe G
Hum Pathol; 2020 May; 99():88-97. PubMed ID: 32246989
[TBL] [Abstract][Full Text] [Related]
15. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
Massi D; Brusa D; Merelli B; Falcone C; Xue G; Carobbio A; Nassini R; Baroni G; Tamborini E; Cattaneo L; Audrito V; Deaglio S; Mandalà M
Ann Oncol; 2015 Sep; 26(9):1980-1987. PubMed ID: 26037795
[TBL] [Abstract][Full Text] [Related]
16. Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma.
Eckel-Passow JE; Ho TH; Serie DJ; Cheville JC; Houston Thompson R; Costello BA; Dong H; Kwon ED; Leibovich BC; Parker AS
Cancer Med; 2020 Feb; 9(3):1152-1160. PubMed ID: 31829518
[TBL] [Abstract][Full Text] [Related]
17. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
[TBL] [Abstract][Full Text] [Related]
18. PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?
Erlmeier F; Hartmann A; Autenrieth M; Wiedemann M; Ivanyi P; Steffens S; Weichert W
Med Oncol; 2016 Nov; 33(11):120. PubMed ID: 27696122
[TBL] [Abstract][Full Text] [Related]
19. Coexpression of lymphocyte-activation gene 3 and programmed death ligand-1 in tumor infiltrating immune cells predicts worse outcome in renal cell carcinoma.
Lee CH; Jung SJ; Seo WI; Chung JI; Lee DS; Jeong DH; Jeon Y; Choi I
Int J Immunopathol Pharmacol; 2022; 36():3946320221125588. PubMed ID: 36083857
[TBL] [Abstract][Full Text] [Related]
20. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
